PA-MONROL
24.11.2021 08:02:04 CET | Business Wire | Press release
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) today announced their agreement with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biotech company focused on developing innovative therapies for rare cancers, for the supply of the medical radioisotope no-carrier-added 177 Lu (n.c.a. 177 Lu).
Eczacıbaşı-Monrol entered the theranostic market in 2019 as one of the few producers of Lutetium-177 worldwide and since then has provided an uninterrupted supply of this critical product to patients in many countries. In line with its mission to improve the quality of life of cancer patients globally, the company is establishing strategic partnerships with international pharmaceutical companies and constructing a new production facility compliant with FDA 21 CFR Part 211 quality standards that will have an annual capacity of 60 thousand doses. Thanks to its location close to Istanbul's transportation hub, the new facility will benefit from a worldwide logistics network and agreements with cargo services to 320 destinations worldwide.
Aydin Küçük, General Manager of Eczacıbaşı-Monrol, noted that n.c.a.177 Lu contributes to the company's mission of adding value to human life with leading and innovative approaches in the diagnosis and treatment of critical diseases and added, "To support our growth in this field, we're establishing a new GMP certified facility exclusively for theranostic R&D and production with a new technology that will enable us to maximize our supply of high-quality Lutetium. Sustainability and innovation are two of our core values, and we strive for continuous improvement in our operations and products while trying to serve patients all around the world."
Molecular Targeting Technologies, Inc. (MTTI) CEO, Chris Pak said, " We’ve identified a timely and sustainable supply of a key therapeutic ingredient needed for the development and launch of our lead asset 177 Lu-EBTATE and other EB platform technologies. We are excited to start
this collaboration and build what promises to be a great relationship with a reliable and trusted radioisotope supply partner like Eczacıbaşı-Monrol for the supply of n.c.a.177 Lu.”
About Molecular Targeting Technologies, Inc. (MTTI)
Molecular Targeting Technologies, Inc. is a privately held, rapidly growing, well financed, clinical stage biotech developing targeted radiotherapeutics and diagnostics for rare cancers. We are committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostic assets to improve human health, reduce healthcare costs and reward stakeholders. MTTI expects to be orchestrating multiple clinical trials in 2022. For more information: www.mtarget.com
; www.evathera.com
About Eczacıbaşı-Monrol
Eczacıbaşı-Monrol Nuclear Products Co. is an innovative, international supplier of radiopharmaceuticals for diagnosis and treatment in nuclear medicine. Eczacıbaşı-Monrol is headquartered in Istanbul and delivers customer-oriented service globally.
Monrol exports high quality and a wide spectrum of nuclear medicine products to more than 50 countries around the globe and has manufacturing sites and operational projects in different regions. For more information visit www.monrol.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123006032/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Bolivarian Republic of Venezuela Announces the Initiation of a Comprehensive Public Debt Restructuring Process13.5.2026 22:08:00 CEST | Press release
The Bolivarian Republic of Venezuela announces today its decision to initiate a comprehensive restructuring of its external public debt obligations. CONTEXT & RATIONALE Over the past decade, Venezuela's economy has been severely impacted by external shocks – from the end of the commodity super-cycle to foreign sanctions and COVID-19 – resulting in a sharp economic contraction, a protracted default since 2017, and a ballooning of public sector liabilities. The country nonetheless possesses a strong economic potential, including unique hydrocarbon and mineral endowments. A recovery is underway, and Venezuela is committed to accelerating it through a comprehensive reform agenda in support of growth, fiscal sustainability, monetary stabilization, and enhanced governance. Restoring public debt sustainability is central to this agenda: the current debt overhang constrains external financing, limits public investment capacity, and prevents full re-engagement with the international financial s
Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 21:00:00 CEST | Press release
Proposed acquisition extends Boomi’s AI gateway capabilities, enabling enterprises to govern massive volumes of traffic for production-ready AI Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, securi
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 19:27:00 CEST | Press release
BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the classApproval of BEQALZI marks the first new BCL2 inhibitor approved in a decade in the U.S. and the only BCL2 inhibitor approved in MCL, aiming to set a new standard of innovation BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, a
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 16:30:00 CEST | Press release
Orchestration capabilities simplify workflows, while advanced agent connectivity and an enhanced context layer activate data and scale AI Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this visio
Boomi and Red Hat Collaborate on Production-Ready Agentic AI13.5.2026 16:30:00 CEST | Press release
Companies team to deliver a unified, enterprise-scale agentic stack to help organizations with managing data sovereignty and optimizing AI costs Boomi, the data activation company for AI, and Red Hat, the world’s leading provider of open source solutions, today announced a strategic collaboration to deliver a single, integrated stack for deploying agentic AI at scale. For many organizations, building production AI today means assembling numerous disconnected vendor choices spanning agent builders, orchestration tools, governance platforms, model providers, integration middleware, and security infrastructure, which can lead to data leaks and unpredictable costs. Boomi and Red Hat are working together to simplify AI innovation for customers by bringing together Boomi’s Agentstudio with the enterprise-grade power of Red Hat AI. This makes it easier for organizations to build agents that solve real business problems while supporting corporate standards for sovereignty, infrastructure flexi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom